425: BridgeBio Oncology Therapeutics to Go Public Through Merger with Helix Acquisition Corp. II

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a definitive business combination agreement to create a publicly listed biotechnology company focused on advancing RAS and PI3K-targeting medicines.

Summary

• BridgeBio Oncology Therapeutics (BBOT) is set to become a publicly listed company through a business combination with Helix Acquisition Corp. II (HLXB).
• The transaction is expected to provide BBOT with approximately $550 million in cash, assuming no redemptions by Helix's public shareholders.
• This includes approximately $196 million held in Helix's trust account and $260 million from a private investment in public equity (PIPE) financing led by Cormorant Asset Management.
• The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will focus on developing therapies for RAS and PI3K malignancies.
• BBOT's lead programs include BBO-8520, BBO-10203, and BBO-11818, which are in Phase 1 clinical trials or planned for IND submission.
• The transaction is expected to close in the third quarter of 2025, subject to stockholder approvals and other customary closing conditions.
• Assuming a share price of $10.36 per share and no redemptions, BBOT is expected to have an implied pro forma equity value of approximately $949 million at closing.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the business combination providing significant funding for BBOT's pipeline, the involvement of reputable institutional investors, and the potential for BBOT's therapies to address unmet needs in oncology. However, risks associated with clinical development and regulatory approval temper the overall sentiment.

Positives

• The business combination provides BBOT with significant capital to advance its clinical programs.
• The PIPE financing is led by prominent institutional investors, indicating confidence in BBOT's pipeline and management team.
• BBOT's pipeline targets RAS and PI3K malignancies, which are prevalent oncogenes in human tumors.
• BBOT's lead programs have novel mechanisms of action and are in Phase 1 clinical trials.
• The combined company will have a strong cash position to execute its development plans into mid-2027.
• BBOT's management team has a proven track record of developing new medicines.

Negatives

• The transaction is subject to stockholder approvals and other closing conditions, which could delay or prevent its completion.
• The implied pro forma equity value is dependent on the share price and assumes no redemptions by Helix's public shareholders.
• BBOT has a limited operating history and has not generated any revenue.
• The development of BBOT's product candidates is subject to regulatory approval and clinical trial risks.
• BBOT faces competition from other companies developing therapies for RAS and PI3K malignancies.
• The market opportunities for BBOT's product candidates may be limited to certain patient subsets.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact the transaction.
• Regulatory approvals may be delayed or subject to unanticipated conditions.
• The anticipated benefits of the business combination may not be realized.
• There are risks relating to the uncertainty of the projected financial information with respect to BBOT and the combined company.
• BBOT's product candidates may not receive regulatory approval or achieve adequate market acceptance.
• The amount of redemption requests made by Helix's public shareholders could impact the cash position of the combined company.
• Uncertainty regarding outcomes of BBOTs ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates.

Future Outlook

BBOT expects net proceeds from the transaction to provide the capital needed to accelerate the development of three lead programs: BBO-8520, BBO-10203, and BBO-11818, with a cash runway into mid-2027.

Management Comments

• Eli Wallace, PhD., Chief Executive Officer of BBOT, said 'This financing and transaction mark a significant milestone for our company. We are profoundly grateful to the patients who participate in our trials, our dedicated BBOT team members, and our investors. We believe this transaction is the optimal path to advance our programs and make a meaningful impact on patients affected by deadly cancers.'
• Bihua Chen, Founder and Chief Executive Officer of Cormorant, and Chief Executive Officer of Helix, said 'BBOT's team has some of the brightest minds in oncology, with a proven track record of developing new medicines. The companys pipeline has the potential for paradigm-shifting impact on the treatment of some of the highest prevalence malignancies and we look forward to seeing patient impact further materialize as the clinical trials move forward.'

Industry Context

This announcement reflects the ongoing trend of biotech companies utilizing SPAC mergers to access public markets and fund drug development programs, particularly in the high-growth oncology sector. The focus on RAS and PI3K pathways aligns with the industry's increasing interest in targeted therapies for genetically defined cancers.

Comparison to Industry Standards

• The $949 million pro forma equity value is comparable to other clinical-stage biotech companies focused on oncology.
• The $260 million PIPE financing is a significant investment, reflecting strong institutional interest in BBOT's pipeline.
• BBOT's focus on RAS and PI3K pathways aligns with industry trends, as these pathways are implicated in a significant proportion of cancers.
• Companies like Mirati Therapeutics and Revolution Medicines are also targeting RAS mutations, but BBOT's approach with BBO-8520, BBO-10203, and BBO-11818 offers a differentiated strategy.
• The expected cash runway into mid-2027 is typical for biotech companies at this stage of development, providing sufficient funding for key clinical milestones.

Stakeholder Impact

• Shareholders of BBOT will benefit from the increased access to capital and liquidity as a publicly traded company.
• Patients with RAS and PI3K malignancies may benefit from the development of new therapies.
• Employees of BBOT will have the opportunity to work for a growing company with a promising pipeline.
• Investors in Helix Acquisition Corp. II will have the opportunity to participate in the potential upside of BBOT's development programs.

Next Steps

• Helix II intends to prepare and file with the SEC a registration statement on Form S-4.
• Helix II will mail a definitive proxy statement/prospectus relating to the Business Combination to its shareholders.
• The transaction is subject to the approval of the stockholders of both BBOT and Helix.
• BBOT expects to dose the first patient with BBO-11818 in the first half of 2025.
• The business combination is expected to be completed in the third quarter of 2025.

Key Dates